The patent issuance is a positive IP signal for a micro-cap medical device company, but without financial data or commercial traction updates, the stock impact is likely modest. Monitor for future revenue reports or partnership announcements that could leverage the strengthened patent position. The company's ability to commercialize its technology and secure financing remains the key risk.
Price Chart
Executive Summary
Vivos Therapeutics announced the issuance of US Patent No. 12,697,190, a continuation patent that broadens protection for its Vivos CARE oral medical device technology used to treat obstructive sleep apnea. This strengthens the company's IP moat around its FDA-cleared devices, but the filing contains no financial data, guidance, or near-term revenue catalysts, making it a modestly positive but non-material event for a $4M market cap company.
Key Facts
- US Patent No. 12,697,190 issued, a continuation of foundational Patent No. 12,048,608 (issued July 30, 2024)
- Patent broadens design-independent claims for Vivos CARE vibrational oral appliance platform
- Vivos CARE devices have FDA 510(k) clearances for severe OSA in adults and moderate-to-severe OSA in children (ages 6-17)
- Approximately 80% of patients treated with Vivos CARE devices achieve significant reductions or complete resolution of OSA symptoms
- Over 5 million CPAP units have been subject to FDA-mandated recalls since 2021
- Market cap is approximately $4M with minimal institutional ownership (top holder Commonwealth Equity Services at $19,320)
Financial Impact
No financial figures provided in the filing. IP strengthening is qualitative with no near-term revenue or cost impact disclosed.
Risk Factors
- Patent may be challenged, invalidated, or circumvented by competitors
- Company may be unable to effectively market products or increase revenues
- Vivos may be unable to secure additional financing to continue operations or maintain its Nasdaq listing
- No financial data or guidance provided in this filing to assess commercial progress
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 10 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (VVOS) — Batch item 1 | 0001493152-26-037173 |
| Exhibit: ex99-1.htm | 0001493152-26-037173 |
| Document: 0001493152-26-037173-index-headers.html | 0001493152-26-037173 |
| Document: 0001493152-26-037173-index.html | 0001493152-26-037173 |
| Document: 0001493152-26-037173.txt | 0001493152-26-037173 |
| 8-K Filing (VVOS) — Batch item 6 | 0001493152-26-037173 |
| Exhibit: ex99-1.htm | 0001493152-26-037173 |
| Document: 0001493152-26-037173-index-headers.html | 0001493152-26-037173 |
| Document: 0001493152-26-037173-index.html | 0001493152-26-037173 |
| Document: 0001493152-26-037173.txt | 0001493152-26-037173 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 8-K | $0.1347 | awaiting T+60 | — | $0.1280 (−4.97%) |
Oct 19, 2026 6d ago | Press Release | $0.1410 | awaiting T+60 | — | $0.1280 (−9.22%) |
Oct 19, 2026 6d ago | 8-K | $0.1406 | awaiting T+60 | — | $0.1280 (−8.96%) |
Oct 15, 2026 11d ago | 8-K | $0.1428 | awaiting T+60 | — | $0.1280 (−10.36%) |
Oct 15, 2026 11d ago | Press Release | $0.1428 | awaiting T+60 | — | $0.1280 (−10.36%) |
Sep 30, 2026 25d ago | 8-K | $0.1490 | awaiting T+60 | — | $0.1280 (+14.09%) |
Aug 28, 2026 8w ago | Press Release | $0.2249 | awaiting T+60 | — | $0.1280 (−43.09%) |
Aug 21, 2026 9w ago | 8-K | $0.2768 | awaiting T+60 | — | $0.1280 (−53.76%) |
Aug 14, 2026 10w ago | Press Release | $0.3012 | awaiting T+60 | — | $0.1280 (+57.50%) |
Aug 14, 2026 10w ago | Press Release | $0.3433 | awaiting T+60 | — | $0.1280 (−62.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers